Do Glioma Patients Derive Any Therapeutic Benefit From Taking a Higher Cumulative Dose of Temozolomide Regimens?: A Meta-Analysis

Temozolomide (TMZ) is an oral alkylating agent with established effects on the central nervous system of glioblastoma (GBM) patients. Clinical trials have demonstrated a significant impact on overall survival (OS) with TMZ. Ever since, several TMZ regimens have been designed to improve treatment eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Hao, Du, Shasha, Liao, Guixiang, Xie, Xiao, Ren, Chen, Yuan, Ya Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2015
Materias:
4200
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602866/
https://www.ncbi.nlm.nih.gov/pubmed/25997057
http://dx.doi.org/10.1097/MD.0000000000000827

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602866/
https://www.ncbi.nlm.nih.gov/pubmed/25997057
http://dx.doi.org/10.1097/MD.0000000000000827

Ejemplares similares